ARTICLE | Clinical News

Pixykine PIXY321 data

April 4, 1994 7:00 AM UTC

IMNX (Seattle) published results of a Phase I/II trial in 23 evaluable patients who were receiving their first chemotherapy for sarcoma.

As reported in the Journal of Clinical Oncology, the fusion cytokine ameliorated the suppression of bone marrow function. Neutropenia and cumulative loss of platelets were ameliorated, allowing multiple courses of chemotherapy without major antibiotic or transfusion support. ...